LENZ Therapeutics (LENZ) Net Cash Flow (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Net Cash Flow of -$407000.0 for Q1 2026, down 114.11% year-over-year from $2.9 million in Q1 2025, and down 85.0% quarter-over-quarter from -$220000.0 in Q4 2025.
LENZ Therapeutics (LENZ) Net Cash Flow (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Net Cash Flow for 7 consecutive years, with -$407000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 114.11% year-over-year to -$407000.0; the TTM figure through Mar 2026 stood at $1.6 million (up 100.91% YoY), while the FY2025 annual figure was $4.9 million, up 133.0% from the prior year.
- Net Cash Flow eased to -$407000.0 in Q1 2026 per LENZ's latest filing, from -$220000.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $165.3 million in Q1 2024 and bottomed at -$191.9 million in Q1 2022.
- Historically, Net Cash Flow has averaged -$20.5 million across 5 years, with a median of -$12.3 million in 2025.
- Annual changes were most pronounced in 2022 — Net Cash Flow sank 246.27% — and 2023, when it soared 136.67%.
- LENZ Therapeutics' Net Cash Flow stood at -$8.7 million in 2022, then advanced by 11.0% to -$7.7 million in 2023, then sank by 170.99% to -$20.9 million in 2024, then soared by 98.95% to -$220000.0 in 2025, then plunged by 85.0% to -$407000.0 in 2026.
- Business Quant data shows LENZ's Net Cash Flow at -$407000.0 in Q1 2026, -$220000.0 in Q4 2025, and -$12.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | -564,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -564,000.00 |
| Jun 30, 2026 | -564,000.00 |
| Mar 31, 2026 | -407,000.00 |
| Mar 31, 2026 | -407,000.00 |
| Dec 31, 2025 | -220,000.00 |
| Dec 31, 2025 | -220,000.00 |
| Sep 30, 2025 | -12.32 Mn |
| Sep 30, 2025 | -12.32 Mn |
| Jun 30, 2025 | 14.57 Mn |
| Jun 30, 2025 | 14.57 Mn |
| Mar 31, 2025 | 2.88 Mn |
| Mar 31, 2025 | 2.88 Mn |
| Dec 31, 2024 | -20.89 Mn |
| Dec 31, 2024 | -20.89 Mn |
| Sep 30, 2024 | -42.99 Mn |
| Sep 30, 2024 | -42.99 Mn |
| Jun 30, 2024 | -116.32 Mn |
| Jun 30, 2024 | -116.32 Mn |
| Mar 31, 2024 | 165.33 Mn |
| Mar 31, 2024 | 165.33 Mn |